Boundless Bio, Inc. (BOLD)
(Delayed Data from NSDQ)
$3.85 USD
+0.04 (1.05%)
Updated Jul 31, 2024 04:00 PM ET
After-Market: $3.84 -0.01 (-0.26%) 7:54 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
[BOLD]
Reports for Purchase
Showing records 81 - 89 ( 89 total )
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Industry: Unclassified
Q2; First Data from XLMTM and Crigler-Najjar Studies by Year?s End
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Unclassified
The Week Ahead in Life Sciences: Upcoming Events for the Week of July 31
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Unclassified
The Week Ahead in Life Sciences: Upcoming Events for the Week of July 24
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Unclassified
1Q, Initial Clinical Data Coming Next Half, Reiterate OP
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Unclassified
Q4 Financials; Clinical Programs on Track to Provide Clinical Data in 2017; Reiterate OUTPERFORM and $20 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Unclassified
Q3 Financials; IND submission for Three Programs Ahead, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Unclassified
Q2 Financials, Pompe Program Set to Enter the Clinic in Q3
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Unclassified
Initiating Coverage with an OUTPERFORM Rating and $20 Price Target; Daring to Treat Life-Threatening Diseases with AAV Gene Therapy
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D